Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: deuterium stabilised enantiomers - Poxel

Next Previous
Drug Profile

Research programme: deuterium stabilised enantiomers - Poxel

Alternative Names: Deuterated bupropion; Deuterated CC11006; Deuterated inolitazone; Deuterated mitoglitazone; Deuterated MSDC 0160; Deuterium stabilised enantiomer bupropion; Deuterium stabilised enantiomer CC 11006; Deuterium stabilised enantiomer inolitazone; Deuterium stabilised enantiomer mitoglitazone; Deuterium stabilised enantiomer MSDC 0160; DRX 184; DRX 195; DRX-194

Latest Information Update: 28 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DeuteRx
  • Developer Celgene Corporation; DeuteRx; Poxel
  • Class Indans; Piperidines; Small molecules; Thiazolidinediones
  • Mechanism of Action Acetylcholinesterase inhibitors; Adrenergic receptor antagonists; AMP activated protein kinase stimulants; Dopamine uptake inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Mitochondrial protein inhibitors; Mitochondrial protein stimulants; Peroxisome proliferator-activated receptor gamma agonists; Platelet ADP receptor antagonists; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Metabolic disorders
  • Discontinued Acute coronary syndromes; Alzheimer's disease; CNS disorders; Inflammation; Major depressive disorder; Sickle cell anaemia; Type 2 diabetes mellitus

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for preclinical development in Metabolic-disorders in France
  • 28 Oct 2022 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top